Platelet mass has prognostic value in patients with myelodysplastic syndromes.
Platelet mass (mean platelet volume x platelet count) can be derived from data obtained from the routine full blood count and separates patients with myelodysplastic syndromes (MDS) at diagnosis into three distinct prognostic groups: low platelet mass group - median survival 5 months and 5-year survival 0%; intermediate platelet mass group - median survival 30 months and 5-year survival 34%; high platelet mass group median survival - not reached at 82 months follow-up with a 5-year survival of 82%. These data provide a simple rapid prognostic index at the time of diagnosis in MDS.
Bowles
Kristian M
KM
Department of Haematology, Addenbrooke's Hospital, Cambridge, UK.
Warner
Brian A
BA
Baglin
Trevor P
TP
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001792:Blood Platelets / Q000473:pathology*; D048429:Cell Size; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000097:blood*; D010976:Platelet Count; D011379:Prognosis; D016019:Survival Analysis